Next-Gen Cancer Immunotherapy Company Banks $75 Million Oversubscribed Series B Round

iTeos Therapeutics SA announced on 6/20/2018 the completion of an oversubscribed $75 million (€64 million) Series B financing led by MPM Capital, with participation from additional new investors HBM Partners, 6 Dimensions Capital and Curative Ventures.